BOSTON, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...
The last time I spoke about Praxis Precision Medicines, Inc. (PRAX), it was in a Seeking Alpha article entitled "Praxis: Still A 'Hold' Despite Interim Analysis Setback Of Ulixacaltamide." At that ...
BOSTON, May 11, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback